The clinically validated RetinaRisk software solution empowers the global diabetic population of 463 million to calculate and better understand their individualized risk of developing sight-threatening diabetic retinopathy, one of the leading causes of blindness in the world today. RetinaRisk also serves healthcare professionals as a decision support tool to identify high-risk patients and provide personalized care. RetinaRisk also enables hospitals and national healthcare systems to streamline diabetic retinopathy eye screening and make it more efficient and cost-effective by ensuring that the right patient receives the right treatment at the right time.
Our Technology Offers
The Software Solution Revolutionizing Diabetic Eye Care
This technology is a software solution, centered on a clinically-validated algorithm, that accurately calculates the risk of sight-threatening diabetic retinopathy, one of the leading causes of blindness in the world. Based on an user-friendly individualized risk calculation, the solution facilitates early detection of the eye disease and allows healthcare professionals to provide personalized care to enhance patient’s clinical safety. This solution can save the eyesight of millions of people living with diabetes.
The unique software solution serves as a decision support tool to identify low, medium, and high-risk patients and it charts the key risk factors for each patient. It can also recommend variable eye screening intervals, based on each patient’s risk profile, ensuring that the right patient receives the right care at the right time.
The solution also supports doctor/patient dialogue by vividly demonstrating, in an easy-to-visualize way, how modifying key risk factors such as blood glucose (HbA1c) and blood pressure, can significantly lower the risk of vision loss. This motivates patients towards enhanced diabetes care and becoming more active participant in their own wellness journey.
The company offers a novel, sustainable solution in an area of high unmet medical need, where today’s methods alone are unsustainable. It can lead to enhanced clinical outcomes, increased diabetic eye screening capacity and potential healthcare cost savings of up to 60%.